Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease

Published 08/09/2022, 18:53
Updated 08/09/2022, 19:41
© Reuters.  Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease

© Reuters. Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease

  • Regeneron Pharmaceuticals Inc (NASDAQ: NASDAQ:REGN) and Sanofi (EPA:SASY) SA (NASDAQ: SNY) presented detailed results from the second of two Phase 3 trials (PRIME) evaluating Dupixent (dupilumab) in adults with uncontrolled prurigo nodularis.
  • Prurigo nodularis patients experience intense, persistent itch with thick skin lesions (nodules) that can cover most of the body.
  • Related: Sanofi-Regeneron's Flagship Drug Shows Consistent Efficacy, Safety Profile At Two Years For Asthma In Kids.
  • These data, consistent with the detailed data from the first Phase 3 trial (PRIME2) in prurigo nodularis, show that Dupixent significantly reduced itch and skin lesions at 24 weeks.
    • At 24 weeks, among patients treated with Dupixent in the trial:
    • 60% of the patients experienced a clinically meaningful reduction in itch from baseline, the primary endpoint, compared to placebo patients (18%).
    • Nearly three times as many (48%) achieved clear or almost clear skin, a key secondary endpoint, compared to placebo patients (18%).
    • The safety results of the trial were generally consistent with the known safety profile of Dupixent in its approved dermatological indication.
  • Regulatory submissions are already under review by the European Commission and the FDA, with the FDA granting a Priority Review and a target action date of September 30.
  • Price Action: REGN shares are up 19.10% at $710.10, and SNY stock is down 0.74% at $40.17 on the last check Thursday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.